GLP-1 Peptide Market Trends: Efficacy, Brand Competition & Supply Chain Insights
Published: July 12, 2026 23:22
Author: Birgit Vazquez
Title: GLP-1 Peptide Market Trends: Efficacy, Brand Competition & Supply Chain Insights Abstract: The GLP-1 peptide market is surging, driven by proven efficacy in diabetes and obesity management. Brand competition intensifies between Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Mounjaro/Zepbound), with tirzepatide showing superior weight loss (up to 22.5% vs. 15%). Key differentiators include receptor selectivity and half-life. Supply chain bottlenecks persist, with FDA-listed facilities and third-party certificate of analysis (CoA) critical for quality. Industry trends favor oral formulations and biosimilars, demanding rigorous vendor audits for purity (>99%) and cold-chain logistics compliance.